KOREA WHO

Lee Sang-hoon is the CEO of ABL Bio.

He aims to make ABL Bio the first among domestic biotech platform companies to earn royalties from new drug development.

He was born in January 1963.

Lee earned his bachelor's degree in Biology Education from Seoul National University and received a master's degree in Animal Embryology from the same university's graduate school. He later obtained a Ph.D. in Molecular Biology, Cell Biology, and Developmental Biology from Ohio State University in the United States.

He gained research experience as a medical researcher at Harvard University, UC San Francisco, and Stanford University. He then served as a senior researcher at several renowned pharmaceutical and global biotech companies, including Chiron (formerly Novartis), AstraZeneca, Genentech, and Exelixis.

Lee co-founded the new drug developer PharmAbcine and served as its Executive Vice President. In 2013, he took charge of the biotech business at Hanwha Chemical. After Hanwha discontinued its biotech operations, he established ABL Bio in 2016 with a focus on bispecific antibody therapeutics.

Just two years after its founding, ABL Bio secured an investment of KRW 99 billion (US$ 71.2 million).

In 2024, he led an institutional investment round worth KRW 140 billion (US$ 100.7 million) to support the development of bispecific antibody-drug conjugates (ADCs).

#ABLbio #LeeSanghoon #biotech #bispecificantibody #ADC #drugdevelopment #investment #platformbiotech #Hanwha #PharmAbcine